awmsg logo

clofarabine (Evoltra®)

Reference No. 92

Publication date:

Appraisal information

clofarabine (Evoltra®) 1 mg/ml concentrate for solution for infusion

Company: Bioenvision Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 17/05/2007
AWMSG meeting date: 12/06/2007
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0107
Ratification by Welsh Government: 30/07/2007

Current Progress

Ratification by
Welsh Government

AWMSG advice

Clofarabine (Evoltra®) is recommended for use within NHS Wales for the treatment of acute lymphoblastic leukaemic (ALL) in paediatric patients (≤ 21 yrs) who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Treatment is restricted to patients in whom there is an intention to proceed to stem cell transplantation and who are under the care of a paediatric haemato-oncologist, as it is not cost effective when used for palliation. Its use will be audited and reviewed in 2009.
Final Appraisal Recommendation (FAR)